“Gilead said its twice-yearly HIV prevention shot Yeztugo generated $232 million in sales in the second quarter, topping Wall Street estimates of $221 million.” endpoints.news/gileads-yezt...
Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B
Gilead's Yeztugo generated $232M in Q2, beating estimates, while the company's overall HIV PrEP franchise topped $1B.
endpoints.news